We are developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available today.
Nemvaleukin Alfa - IL-2 Variant
|Indication||Discovery||Preclinical||Phase 1||Phase 2||Phase 3|
|Program||Discovery||Preclinical||Phase 1||Phase 2||Phase 3|
Last updated: November 2023
Cytokine-Based Immunotherapy Candidates
Our commitment extends to advancing a robust portfolio of programs aimed at expanding the horizons of cytokine-based immunotherapy, especially for cancers where treatment options remain limited. Use the links below to learn more about our portfolio of cytokine-based immunotherapy candidates.
Nemvaleukin, an engineered IL-2 variant, maximizes anti-cancer potential and minimizes toxicity by activating CD8 T cells and NK cells, making it a promising candidate in cancer immunotherapy.